Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BND-35 |
Synonyms | |
Therapy Description |
BND-35 is an antibody targeting ILT3 (LILRB4), which potentially induces antitumor immune activity (Cancer Res (2024) 84 (6_Supplement): 3920). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BND-35 | BND35|BND 35 | BND-35 is an antibody targeting ILT3 (LILRB4), which potentially induces antitumor immune activity (Cancer Res (2024) 84 (6_Supplement): 3920). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06274437 | Phase I | BND-35 + Cetuximab BND-35 + Nivolumab BND-35 | A Study of BND-35 in Participants With Advanced Solid Tumors | Recruiting | ISR | 0 |